Publication date: 1 November 2026 Source: Drug and Alcohol Dependence, Volume 288 Author(s): Dustin K. Miracle, Svetla Slavova, Patricia R. Freeman, Sergey Tarima
County-level context and differential policy impacts on buprenorphine use among medicaid enrollees with opioid use disorder in Kentucky, 2018–2025. // Drug and Alcohol Dependence. – URL: https://www.sciencedirect.com/science/article/pii/S0376871626003753?dgcid=rss_sd_all
County-level context and differential policy impacts on buprenorphine use among medicaid enrollees with opioid use disorder in Kentucky, 2018–2025. Drug and Alcohol Dependence. https://www.sciencedirect.com/science/article/pii/S0376871626003753?dgcid=rss_sd_all
“County-level context and differential policy impacts on buprenorphine use among medicaid enrollees with opioid use disorder in Kentucky, 2018–2025.” Drug and Alcohol Dependence.
@article{article43566,
title = {County-level context and differential policy impacts on buprenorphine use among medicaid enrollees with opioid use disorder in Kentucky, 2018–2025},
journal = {Drug and Alcohol Dependence},
url = {https://www.sciencedirect.com/science/article/pii/S0376871626003753?dgcid=rss_sd_all}
}
Acta Pharmacologica Sinica, Published online: 16 November 2026; doi:10.1038/s41401-026-01953-z IRAK4 inhibitor DW18134 ameliorates diffuse large B-cell lymphoma in combination with ibrutinib and overcomes acquired resistance to ibrutinib
Acta Pharmacologica Sinica, Published online: 16 November 2026; doi:10.1038/s41401-026-01958-8 Artificial intelligence aids multi-omics data integration in cancer drug discovery and development: from targets to drug synergy
Nature Reviews Drug Discovery, Published online: 13 November 2026; doi:10.1038/d41573-026-00179-2 The NIH’s P. J. Brooks discusses the challenges and opportunities ahead for gene therapies and gene editing for diseases of no commercial interest.
Nature Reviews Drug Discovery, Published online: 13 November 2026; doi:10.1038/d41573-026-00181-8 Merck and Moderna’s intismeran autogene succeeded in a landmark melanoma trial, but the oncology community still has more questions than...